Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Freegold Intersects 3.62 g/t Au over 42m and 1.23 g/t Au over 170.7m (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

CSE:AGN - Post Discussion

Algernon Pharmaceuticals Inc. > AGN trading green + presentations from Wonderland Miami
View:
Post by waves1 on Nov 07, 2022 4:48pm

AGN trading green + presentations from Wonderland Miami

Check out AGN's presentations from Wonderland Miami from last week:

Business Presentation: https://algernonpharmaceuticals.com/wp-content/uploads/2018/01/Wonderland-Algernon-Christopher-Moreau-Business-Keynote-PPT-FINAL-For-Nov-4th.pdf

Science Presentation: https://algernonpharmaceuticals.com/wp-content/uploads/2018/01/Wonderland-Algernon-Christopher-Moreau-Science-Keynote-PPT-FINAL-For-Nov-5th.pdf


AGN has broken down its presentations into the business aspect and science aspect for a more in-depth look into both.

As the leading sponsor, Wonderland was a significant exposure opportunity for AGN, especially given they are the first company globally to investigate DMT as a possible treatment for stroke.

The positive preclinical data that is driving AGN's Phase I clinical study of DMT for the treatment of stroke was reviewed during the presentations by AGN CEO Christopher Moreau and Dr. Rick Strassman, author of "DMT: The Spirit Molecule" and AGN consultant.

Be the first to comment on this post
Algernon Pharmaceuticals Inc.